[
    [
        {
            "time": "",
            "original_text": "复宏汉霖将在香港上市，拟融资超30亿元？本土创新四大梯队长啥样？",
            "features": {
                "keywords": [
                    "复宏汉霖",
                    "香港上市",
                    "融资",
                    "本土创新"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复宏汉霖将在香港上市，拟融资超30亿元？本土创新四大梯队长啥样？",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]医药行业周报：进入年报期 关注业绩的确定性和持续性",
            "features": {
                "keywords": [
                    "医药行业",
                    "年报",
                    "业绩",
                    "确定性",
                    "持续性"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药行业周报：进入年报期 关注业绩的确定性和持续性",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "尔康制药：自查虚增净利2.3亿",
            "features": {
                "keywords": [
                    "尔康制药",
                    "自查",
                    "虚增净利"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "尔康制药：自查虚增净利2.3亿",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]医药行业周报：CAR-T疗法再进优先审批 临床价值进一步凸显",
            "features": {
                "keywords": [
                    "医药行业",
                    "CAR-T疗法",
                    "优先审批",
                    "临床价值"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药行业周报：CAR-T疗法再进优先审批 临床价值进一步凸显",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[强于大市评级]医药生物行业投资策略：优选“业绩拐点+估值修复”品种 巧避”雷区”",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "业绩拐点",
                    "估值修复",
                    "雷区"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[强于大市评级]医药生物行业投资策略：优选“业绩拐点+估值修复”品种 巧避”雷区”",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[强于大市评级]医药生物行业研究周报：拥抱二线白马 守望一线龙头",
            "features": {
                "keywords": [
                    "医药生物",
                    "二线白马",
                    "一线龙头"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[强于大市评级]医药生物行业研究周报：拥抱二线白马 守望一线龙头",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "注射剂一致性评价推进 出口企业或受益",
            "features": {
                "keywords": [
                    "注射剂",
                    "一致性评价",
                    "出口企业",
                    "受益"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "注射剂一致性评价推进 出口企业或受益",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业：创新和终端格局重构两条主线选股",
            "features": {
                "keywords": [
                    "医药行业",
                    "创新",
                    "终端格局",
                    "重构",
                    "选股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业：创新和终端格局重构两条主线选股",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]